Roivant Sciences (ROIV) Competitors $12.53 +0.71 (+6.01%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ROIV vs. BNTX, TEVA, BGNE, VTRS, MRNA, SMMT, GMAB, RDY, PCVX, and CTLTShould you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Moderna (MRNA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Roivant Sciences vs. BioNTech Teva Pharmaceutical Industries BeiGene Viatris Moderna Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Vaxcyte Catalent BioNTech (NASDAQ:BNTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings. Is BNTX or ROIV more profitable? Roivant Sciences has a net margin of 3,827.42% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-15.16% -2.35% -2.05% Roivant Sciences 3,827.42%-14.65%-13.19% Does the MarketBeat Community prefer BNTX or ROIV? BioNTech received 85 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 45.48% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformBioNTechOutperform Votes13645.48% Underperform Votes16354.52% Roivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% Which has more volatility & risk, BNTX or ROIV? BioNTech has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Do insiders and institutionals believe in BNTX or ROIV? 15.5% of BioNTech shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, BNTX or ROIV? Roivant Sciences has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$4.13B6.56$1.01B-$2.10-53.87Roivant Sciences$124.79M74.25$4.35B$5.652.22 Do analysts recommend BNTX or ROIV? BioNTech presently has a consensus price target of $138.79, suggesting a potential upside of 22.68%. Roivant Sciences has a consensus price target of $17.93, suggesting a potential upside of 43.09%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.81Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the media prefer BNTX or ROIV? In the previous week, BioNTech had 22 more articles in the media than Roivant Sciences. MarketBeat recorded 28 mentions for BioNTech and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.52 beat BioNTech's score of 0.35 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRoivant Sciences beats BioNTech on 11 of the 19 factors compared between the two stocks. Ad DTII've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROIV vs. The Competition Export to ExcelMetricRoivant SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.27B$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio2.2211.01105.0417.81Price / Sales74.25361.871,235.79158.52Price / CashN/A52.5940.3536.29Price / Book1.6610.377.086.50Net Income$4.35B$153.60M$119.58M$226.22M7 Day Performance11.88%4.59%2.25%4.03%1 Month Performance7.83%-6.28%-2.34%4.92%1 Year Performance39.22%33.39%33.95%29.30% Roivant Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROIVRoivant Sciences3.337 of 5 stars$12.53+6.0%$17.93+43.1%+39.2%$9.27B$124.79M2.22860Insider TradeBNTXBioNTech2.634 of 5 stars$108.20+5.9%$138.79+28.3%+15.5%$25.94B$4.13B-51.526,133Analyst ForecastTEVATeva Pharmaceutical Industries3.004 of 5 stars$17.08+0.3%$19.67+15.1%+81.0%$19.29B$16.77B-20.0937,851Insider TradeBGNEBeiGene3.1896 of 5 stars$194.56+0.2%$247.07+27.0%+4.2%$18.95B$2.46B-23.5810,600Analyst DowngradeVTRSViatris1.4394 of 5 stars$13.26+0.9%$13.33+0.6%+42.7%$15.82B$15.43B-17.9138,000News CoverageMRNAModerna4.5706 of 5 stars$38.40+4.0%$84.00+118.7%-47.4%$14.78B$6.85B-6.355,600Analyst ForecastOptions VolumeAnalyst RevisionSMMTSummit Therapeutics1.8568 of 5 stars$18.42-1.1%$34.75+88.7%+874.4%$13.58B$700,000.00-67.00105GMABGenmab A/S4.232 of 5 stars$20.47+0.1%$45.20+120.8%-34.5%$13.55B$2.39B19.872,204High Trading VolumeRDYDr. Reddy's Laboratories1.4214 of 5 stars$13.99-2.2%$17.00+21.5%+5.0%$11.68B$3.35B22.3527,048PCVXVaxcyte3.3258 of 5 stars$88.39+2.8%$147.50+66.9%+80.7%$11.02BN/A-19.22160Positive NewsHigh Trading VolumeCTLTCatalent3.0832 of 5 stars$59.66+1.1%$63.40+6.3%+54.0%$10.83B$4.38B-26.4016,900Analyst Downgrade Related Companies and Tools Related Companies BNTX Competitors TEVA Competitors BGNE Competitors VTRS Competitors MRNA Competitors SMMT Competitors GMAB Competitors RDY Competitors PCVX Competitors CTLT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ROIV) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ROIV Stock Alerts